The dose selection represents a significant advancement in the clinical development of azenosertib, supporting the company's registration-intended path. The expanded trial design and confirmatory Phase 3 trial initiation suggest Zentalis is positioning azenosertib for potential accelerated approval. The extended cash runway provides sufficient funding for expected milestones, reducing near-term financing risk.
Price Chart
Executive Summary
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer based on interim data from the DENALI Part 2a trial. The company also announced an expanded trial design (Part 2c) and expects to complete enrollment and provide a topline readout by year-end 2026. The company maintains its cash runway into late 2027.
Key Facts
- Selected 400mg QD 5:2 as optimal dose for azenosertib based on interim data from DENALI Part 2a
- Demonstrated meaningful and clearly differentiated response rate at 400mg vs 300mg dose
- Observed comparable safety profiles between dose groups with improved discontinuation rates
- Expanded DENALI trial to include Part 2c cohort for patients previously treated with taxane-containing regimens
- ASPENOVA Phase 3 confirmatory trial expected to initiate in Q2 2026
- Topline readout from DENALI Part 2 expected by year-end 2026
- Cash runway extended into late 2027 based on $245.9M in cash, cash equivalents, and marketable securities as of December 31, 2025
Financial Impact
No direct financial impact disclosed, but successful development could address a $21,500 patient population market opportunity
Risk Factors
- Clinical trial results may not support accelerated approval
- Phase 3 ASPENOVA trial may not verify clinical benefit, potentially leading to FDA withdrawal of accelerated approval
- Competitive landscape in platinum-resistant ovarian cancer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000017 |
| Exhibit: ex992doseconfirmationpress.htm | 0001725160-26-000017 |
| Document: zntl-20260409.htm | 0001725160-26-000017 |
| Document: 0001725160-26-000017-index-headers.html | 0001725160-26-000017 |
| Document: 0001725160-26-000017-index.html | 0001725160-26-000017 |
| Document: 0001725160-26-000017.txt | 0001725160-26-000017 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.54 (+31.58%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.54 (+28.79%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.54 (−32.40%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.54 (−35.82%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.54 (−37.56%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.54 (−37.56%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.54 (−40.77%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.54 (−40.77%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.54 (−36.47%) |
Apr 17, 2026 23w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.54 (−45.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access